Optimising synchrotron microbeam radiation therapy for cancer treatment

优化癌症治疗的同步加速器微束放射治疗

• 批准号: nhmrc : 606614
• 负责人: Dr Carl Sprung
• 金额: $ 45.48万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/optimising-synchrotron-microbeam-cancer-treatment/94664
• 关键词: Optimising; synchrotron; microbeam; radiation; therapy

Over 50% of cancer patients receive radiotherapy (RT). Tumour control using RT is limited by adverse normal tissue reactions. Unlike conventional RT machines, the Australian synchrotron has the capability to deliver strong radiation in very thin slices, termed microbeam RT (MRT). Tumour control has been obtained in animal models with a remarkable sparing of normal tissue using MRT. We will optimize MRT as a crucial step towards a potentially revolutionary cancer treatment.

超过50%的癌症患者接受放疗（RT）。使用RT的肿瘤控制受到不良正常组织反应的限制。与传统的RT机器不同，澳大利亚同步加速器能够在非常薄的切片中提供强辐射，称为微束RT（MRT）。使用MRT在动物模型中已经获得了肿瘤控制，其中正常组织的显著保留。我们将优化MRT，作为迈向潜在革命性癌症治疗的关键一步。